Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia

Cover Page

Cite item

Full Text

Abstract

Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than 6-9 months, and the Me of progression-free survival (PFS) was about 2 months. The introduction of immune checkpoint inhibitors and targeted therapy changed the prognosis for the life of IMM patients dramatically. The development, studies, and approval of a new original PD-1 inhibitor, prolgolimab, in Russia in 2020 prompted the professional community to conduct a prospective observational study in the Russian Federation to assess its real-world efficacy and safety.

Aim To evaluate the real-world efficacy and safety of prolgolimab in patients with IMM.

Materials and methods. From October 2020 to October 2022, 700 patients with IMM receiving prolgolimab in real clinical settings in oncological institutions of various levels in the Russian Federation were included in the study. The main inclusion criteria were: pathology-confirmed diagnosis of melanoma; metastatic and/or inoperable type; use of prolgolimab outside of clinical trials; and signed informed consent. Objective response rate in the general population and the Intention-to-treat and Per Protocol populations was considered the main criterion for evaluating the efficacy of therapy, and the safety criterion was the incidence of grade 3-4 adverse events (AEs). PFS and OS rates were also assessed. Statistical analysis was performed using the SPSS 25.0 software package.

Results. The objective response rate for the Per Protocol population (with radiographic assessment available) was 42% (n=235/559). Disease progression was reported in 26.7% (n=149) of patients, stabilization in 31.3% (n=175), and disease control in 73.3% of patients with IMM, regardless of the line of therapy. At the follow-up Me of 12 months (0-36), PFS for all patients regardless of the line of therapy was 8 months (95% confidence interval [Cl] 6.537-9.463), 6-month PFS was 55%, and 12-month PFS was 41%. OS Me for all included patients was 32 months, 6-month OS was 82%, and 12-month OS was 69%. Depending on the line of therapy, the OS Me was: line 1 - not reached, line 2-30 months (95% Cl 16.007-43.993), line 3 and subsequent- 22 months (95% Cl 14.264-29.736); p=0.736. According to the CTCAE 5.0 general terminology criteria for AEs, a total of 136/693 (19.6%) AEs of varying degrees were reported, in particular: grade 1-2 - 105/693 (15.2%), grade 3-4 - 25/693 (3.6%), unknown grade - 5/693 (0.7%), as well as one fatal case (0.1%) due to thromboembolism in the vascular center with an unclear (according to the investigator's assessment) relation with prolgolimab.

Conclusion The results obtained at 12 months of follow-up confirm the high efficacy and satisfactory tolerability of prolgolimab in patients with IMM in real-world practice, regardless of the line of therapy and other characteristics.

About the authors

Kristina V. Orlova

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0002-0442-5917

Cand. Sci. (Med.)

Russian Federation, Moscow

Mikhail Iu. Fedyanin

Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center

Email: fedianinmu@mail.ru
ORCID iD: 0000-0001-5615-7806
SPIN-code: 4381-5628

D. Sci. (Med.)

Russian Federation, Moscow; Moscow; Moscow

Konstantin E. Simanenkov

Lipetsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Department Head, Oncologist

Russian Federation, Lipetsk

Aleksandr S. Dergunov

Tver Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Tver

Petr R. Goldshmidt

Lipetsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Deputy Chief doctor, Oncological Dispensary

Russian Federation, Lipetsk

Aleksandra F. Saydullaeva

Tver Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Tver

Darya V. Bogacheva

Voronezh Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Voronezh

Marina A. Yavorskaya

Oncological Dispensary No. 2

Email: krisman03@gmail.com

Deputy Chief Doctor, Oncologist

Russian Federation, Sochi

Artur Z. Azanov

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Kemerovo

Alexander A. Fedenko

Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4927-5585

D. Sci. (Med.)

Russian Federation, Moscow

Larisa V. Bolotina

Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4879-2687

D. Sci. (Med.)

Russian Federation, Moscow

Tatyana I. Deshkina

Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre

Email: krisman03@gmail.com

Cand. Sci. (Med.), Oncologist

Russian Federation, Moscow

Kseniya G. Babina

Volgograd Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head chemotherapy

Russian Federation, Volgograd

Ekaterina A. Kuzevanova

Regional Clinical Oncological Dispensary, Saratov

Email: krisman03@gmail.com

Department Head, Regional Clinical Oncological Dispensary

Russian Federation, Saratov

Liudmila G. Zhukova

Loginov Moscow Clinical Scientific Center

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4848-6938

D, Sci, (Med,), Corr, Memb. RAS

Russian Federation, Moscow

Polina S. Feoktistova

Loginov Moscow Clinical Scientific Center

Email: krisman03@gmail.com
ORCID iD: 0000-0002-0340-7119

Cand, Sci, (Med,)

Russian Federation, Moscow

Natalya I. Polshina

Loginov Moscow Clinical Scientific Center

Email: krisman03@gmail.com
ORCID iD: 0000-0001-5417-0425

Oncologist

Russian Federation, Moscow

Ekaterina V. Peganova

Clinical Oncology Hospital

Email: krisman03@gmail.com

Oncologist

Russian Federation, Yaroslavl

Valentina E. Shikina

Vladimirsky Moscow Regional Research Clinical Institute

Email: krisman03@gmail.com

Cand, Sci, (Med,)

Russian Federation, Moscow

Maksim M. Sobolev

Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Moscow

Oleg V. Mironov

Tambov Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tambov

Vera A. Vaschenko

Kostroma Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kostroma

Mariya M. Ershova

Sverdlovsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ekaterinburg

Agniya O. Mezhueva

Moscow Multidisciplinary Clinical Center “Kommunarka”

Email: krisman03@gmail.com

Department Head, oncologist

Russian Federation, Moscow

Svetlana A. Orlova

Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Cheboksary

Denis A. Tantsyrev

Altai Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Barnaul

Darya K. Taskina

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: krisman03@gmail.com

Oncologist

Russian Federation, Chelyabinsk

Antonina A. Teterich

Belgorod Regional Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Belgorod

Elena V. Karabina

Tula Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Tula

Yuliya V. Kostalanova

Samara Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Samara

Marina V. Bogacheva

Vologda Regional Clinical Hospital No. 2

Email: krisman03@gmail.com

Oncologist

Russian Federation, Vologda

Natalia V. Zhukova

Saint Petersburg State University; City Clinical Oncology Dispensary

Email: krisman03@gmail.com
ORCID iD: 0000-0002-0619-2205

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg; Saint Petersburg

Rashida V. Orlova

City Clinical Oncology Dispensary

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4447-9458

D. Sci. (Med.), Prof.

Russian Federation, Saint Petersburg

Maksim V. Zinkevich

Leningrad Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Aleksandr I. Kazmin

Voronezh Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Voronezh

Mikhail V. Volkonskiy

Moscow City Oncological Hospital No. 62

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4060-5015

Head of the Day Hospital

Russian Federation, Moscow

Liya M. Voronkova

Republican Oncological Dispensary, Vladikavkaz

Email: krisman03@gmail.com

Department Head

Russian Federation, Vladikavkaz

Anastasiya S. Karpova

Trans-Baikal Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Chita

Mikhail L. Maleyko

Oncological Dispensary, Shakhty

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Shakhty

Mariya N. Gorshenina

Republican Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Yoshkar-Ola

Elena I. Kryuchkova

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Smolensk

Fedor V. Moiseenko

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncology)

Email: krisman03@gmail.com
ORCID iD: 0000-0003-2544-9042

D. Sci. (Med.)

 

Russian Federation, Saint Petersburg

Yuliya I. Murzina

Oncological Dispensary, Birobidzhan

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Birobidzhan

Shamil I. Musin

Republican Clinical Oncology Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Ufa

Andrey N. Ogloblin

Oryol Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Oryol

Mariya S. Perminova

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kemerovo

Regina A. Dumbrava

Primorsky Regional Oncological Dispensary

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Vladivostok

Sergey A. Emelyanov

Primushko Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Izhevsk

Svetlana A. Protsenko

Petrov National Medical Research Center of Oncology

Email: krisman03@gmail.com

Department Head

Russian Federation, Saint Petersburg

Alexander V. Sultanbaev

Republican Clinical Oncology Center

Email: krisman03@gmail.com
ORCID iD: 0000-0003-0996-5995

Cand. Sci. (Med.)

Russian Federation, Ufa

Anna V. Tarasova

Samara Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Samara

Elena B. Shakhnovich

Korolyov City Hospital

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Korolyov

Marina V. Demchenkova

Irkutsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Irkutsk

Yuliya A. Lozovskaya

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Khedi S. Musaeva

Oncology Center “AiMed”

Email: krisman03@gmail.com

Department Head

Russian Federation, Grozny

Elena M. Pavlova

Vologda Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Vologda

Roman A. Skotnikov

Tula Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tula

Vera V. Chernova

8Regional Clinical Oncological Dispensary, Ryazan

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ryazan

Angelina S. Chichkanova

Nizhny Novgorod Regional Clinical Oncology Center

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Nizhny Novgorod

Adina M. Akhmatova

Oncological Dispensary, Nalchik

Email: krisman03@gmail.com

Oncologist, Oncological Dispensary

Russian Federation, Nalchik

Marina A. Zafirova

Sverdlovsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of Chemotherapy Service

Russian Federation, Ekaterinburg

Andrey A. Mischenko

Primorsky Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital, Primorsky Regional Oncological Dispensary

Russian Federation, Vladivostok

Elena N. Ovsienko

Primushko Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Izhevsk

Viktoriya A. Petrukhnenko

Oncological Dispensary, Komsomolsk-on-Amur

Email: krisman03@gmail.com

Department Head

Russian Federation, Komsomolsk-on-Amur

Oksana A. Syusyukaylova

Ashkhamaf Adyghe Republican Clinical Oncology Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Maykop

Yana A. Tyugina

Ivanovo Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

 

Russian Federation, Ivanovo

Elena A. Shumilkina

Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Cheboksary

Daniil L. Stroyakovskiy

Moscow City Oncological Hospital No. 62

Email: krisman03@gmail.com
ORCID iD: 0000-0003-1973-1092

Cand. Sci. (Med.)

Russian Federation, Moscow

Aleksandr N. Yurchenkov

Moscow City Oncological Hospital No. 62

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Moscow

Pavel L. Baldin

Naberezhnye Chelny Oncological Dispensary - branch of the Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Naberezhnye Chelny

Anastasiya S. Belova

Novgorod Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Veliky Novgorod

Olga V. Diduk

Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Krasnoyarsk

Elena A. Konovalova

Murmansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Murmansk

Lyudmila N. Lebedeva

Arkhangelsk Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Arkhangelsk

Yaroslav A. Li

Clinic Lyadov

Email: krisman03@gmail.com

Oncologist

Russian Federation, Khimki

Viktoriya V. Mashtapa

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Yana A. Mironenkova

Vologda Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Vologda

Kristina V. Narovenkova

Bryansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Bryansk

Olga A. Pavlikova

Republican Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Yoshkar-Ola

Elvira L. Parsadanova

Sakhalin Regional Oncological Dispensary

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Yuzhno-Sakhalinsk

Irina S. Pimonova

Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Obninsk

Anna A. Ruzhnikova

Arkhangelsk Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Arkhangelsk

Irina D. Sivunova

Kamchatka Regional Oncology Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Petropavlovsk-Kamchatsky

Ekaterina P. Soloveva

Arkhangelsk Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Arkhangelsk

Maksim I. Sosnin

Krasnogorsk City Hospital No. 1

Email: krisman03@gmail.com

Oncologist

Russian Federation, Krasnogorsk

Kh. Toita Temirsultanova

Oncology Center “AiMed”

Email: krisman03@gmail.com

Department Head

Russian Federation, Grozny

Makhabbat Zh. Tyulegenova

Orenburg Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Orenburg

Aleksandra V. Khodkevich

Bryansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Bryansk

Nadezhda R. Shakurova

Tomsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tomsk

Sureya N. Efendieva

Republican Cancer Center

Email: krisman03@gmail.com

Deputy Chief Doctor

Russian Federation, Makhachkala

Karine L. Avagimyan

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Ekaterina Р. Anokhina

Regional Clinical Oncology Dispensary, Ulyanovsk

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ulyanovsk

Mariya I. Antoshkina

Republican Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Saransk

Stanislav M. Borzyanitsa

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Kemerovo

Samir K. Dzhentemirov

Stavropol Regional Clinical Oncology Center

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Stavropol

Marina V. Dmitrochenko

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Smolensk

Alla V. Zheleznyak

Nizhny Novgorod Regional Clinical Oncology Center

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Nizhny Novgorod

Yuliya V. Komoza

Bryansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Bryansk

Aleksandr S. Kopanev

Center of Oncology and Medical Radiology

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kirov

Tatyana I. Kornienko

Tambov Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tambov

Margarita A. Krasilnikova

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Kemerovo

Darya A. Lukhmanova

Regional Clinical Oncology Dispensary, Ulyanovsk

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ulyanovsk

Natalya S. Mazur

Sverdlovsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ekaterinburg

Polina M. Markina

Nizhny Novgorod Regional Clinical Oncology Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Nizhny Novgorod

Zhargal S. Mitapov

Buryat Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Ulan-Ude

Svetlana N. Osodoeva

Buryat Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Ulan-Ude

Irina A. Prokopenko

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Kursk

Irina M. Radyukova

Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Omsk

Madina S. Ramazanova

Center of Oncology and Medical Radiology

Email: krisman03@gmail.com

Department Head

Russian Federation, Kirov

Alfiya R. Safarova

Almetyevsk branch of the Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Almetyevsk

Mariya A. Safronova

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Smolensk

Khalimat M. Khabrieva

Republican Oncological Dispensary, Nazran

Author for correspondence.
Email: krisman03@gmail.com

Oncologist

Russian Federation, Nazran

Natalya S. Tsygankova

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Smolensk

Kseniya V. Chermakova

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Tatyana A. Chirkova

Rappoport Novokuznetsk branch of the Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Novokuznetsk

Igor V. Samoylenko

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0001-7150-5071

Cand. Sci. (Med.)

Russian Federation, Moscow

Valeria V. Nazarova

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0003-0532-6061

Cand. Sci. (Med.)

Russian Federation, Moscow

Angelina E. Akhmetyanova

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com

Graduate Student

Russian Federation, Moscow

Lev V. Demidov

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0002-8562-6082

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.doi: 10.1056/NEJMoa1003466
  2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. doi: 10.1056/NEJMoa1103782
  3. Grimaldi AM, Simeone E, Ascierto PA. Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. Melanoma Manag. 2015;2(3):209-15. doi: 10.2217/mmt.15.22
  4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-46. doi: 10.1056/NEJMoa1910836
  5. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626-36. doi: 10.1056/NEJMoa1904059
  6. Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33-44. doi: 10.1016/j.ejca.2019.11.016
  7. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40(12):1825-36. doi: 10.1016/j.ejca.2004.04.030
  8. Teimouri F, Nikfar S, Abdollahi M. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res. 2013;23(5):381-9. doi: 10.1097/CMR.0b013e3283649a97
  9. Xin Y, Huang Q, Zhang P, et al. Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma. Medicine (Baltimore). 2016;95(16):e3406. doi: 10.1097/MD.0000000000003406
  10. Hodi FS, Chiarion-Sileni V, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol. 2022;40(16_suppl):9522-2. doi: 10.1200/JCO.2022.40.16_suppl.9522
  11. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24-34. doi: 10.1056/NEJMoa2109970
  12. Long GV, Stephen Hodi F, Lipson EJ, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023;2(4): EVIDoa2200239. doi: 10.1056/EVIDoa2200239
  13. Guidance. Available at: https://www.nice.org.uk/guidance/ng108. Accessed: 12.02.2023.
  14. Seth R, Agarwala SS, Messersmith H, et al. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023;41(30):4794-820. doi: 10.1200/JCO.23.01136
  15. Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435-48. doi: 10.1016/j.annonc.2020.07.004
  16. Меланома кожи и слизистых оболочек. Режим доступа: https://cr.minzdrav.gov.ru/recomend/546_3. Ссылка активна на 12.02.2024 [Melanoma kozhi i slizistykh obolochek. Available at: https://cr.minzdrav.gov.ru/recomend/546_3. Accessed: 12.02.2024 (in Russian)].
  17. Строяковский Д.Л., Абдулоева Н.Х., Демидов Л.В., и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли: практические рекомендации RUSSCO. 2022;12:287-307 [Stroyakovsky DL, Abduloeva NKh, Demidov LV, et al. Practical guidelines for drug treatment of skin melanoma. Malignant tumours: RUSSCO practical guidelines. 2022;12:287-307 (in Russian)]. doi: 10.18027/2224-5057-2022-12-3s2-287-307
  18. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. Available at: http://www.nice.org.uk/guidance/TA950. Accessed: 12.06.2023.
  19. Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030
  20. Орлова К.В., Федянин М.Ю., Симаненков К.Э., и др. Эффективность 1-й линии терапии пролголимабом у больных метастатической меланомой в реальной клинической практике: промежуточные результаты наблюдательного исследования FORA «FOrteca Real practice Assessment». Современная Онкология. 2022;24(4):413-25 [Orlova KV, Fedyanin M, Simanenkov KE, et al. Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study. Journal of Modern Oncology. 2022;24(4):413-25 (in Russian)]. doi: 10.26442/18151434.2022.4.202035
  21. Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495-503.doi: 10.1001/jamadermatol.2022.0160
  22. Злокачественные новообразования в России в 2021 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 [Zlokachestvennye novoobrazovaniia v Rossii v 2021 g. (zabolevaemost’ i smertnost’). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2022.
  23. Kirkwood JM, Kottschade LA, McWilliams RR, et al. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024;16(1):29-42. doi: 10.2217/imt-2022-0292
  24. Kuzmanovszki D, Kiss N, Tóth B, et al. Anti-PD-1 Monotherapy in Advanced Melanoma-Real-World Data from a 77-Month-Long Retrospective Observational Study. Biomedicines. 2022;10(7):1737. doi: 10.3390/biomedicines10071737
  25. Mohr P, Scherrer E, Assaf C, et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers (Basel). 2022;14(7):1804. doi: 10.3390/cancers14071804
  26. Monestier S, Dalle S, Mortier L, et al. Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. Int J Cancer. 2021;148(11):2789-98. doi: 10.1002/ijc.33467

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Progression free survival (PFS) for all included patients, regardless of line of therapy.

Download (35KB)
3. Fig. 2. PFS for all included patients by line of therapy.

Download (55KB)
4. Fig. 3. Overall survival (OS) for all included patients regardless of line of therapy.

Download (35KB)

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies